ACAD
ACADIA PHARMACEUTICALS INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
ACADIA PHARMACEUTICALS INC (ACAD) is held as common stock by 6 tracked hedge-fund managers, with a combined reported value of ~$1.25B; the largest are Baker Bros. Advisors, Steven Cohen, Ken Griffin. 2 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 1 added, 4 trimmed, 1 closed. 4 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Cooling
Common-stock holders62 also report options
Congress trades4
Price$20.53vs quarter-end-18.85%
Sectors0
This quarter's moves
Top holderBaker Bros. AdvisorsNew0
Added1
Trimmed / sold5
Common-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $1.09B5.5% of portfolio42,912,9042026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Baker Bros. Advisors | $1.09B | 5.5% | Hold |
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $2.05M— of portfolio81,0002026 Q2
Value $506.0K— of portfolio20,0002026 Q2
Value $359.3K— of portfolio14,2002026 Q2
Value $359.3K— of portfolio14,2002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $2.05M | — | — |
| Ken GriffinPUT | $506.0K | — | — |
| Steven CohenCALL | $359.3K | — | — |
| Steven CohenPUT | $359.3K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.